TRCT
CRBP icon

Tower Research Capital (TRC)’s Corbus Pharmaceuticals CRBP Stock Holding History

Tower Research Capital (TRC)’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.42K Buy
+684
New +$5.76K ﹤0.01% 4057
2025
Q3 		– Sell
-4,833
Closed -$33.3K – 5271
2025
Q2 		$33.3K Buy
4,833
+2,002
+71% +$14.5K ﹤0.01% 3324
2025
Q1 		$15K Sell
2,831
-1,895
-40% -$16.7K ﹤0.01% 3247
2024
Q4 		$55.8K Sell
4,726
-8,126
-63% -$136K ﹤0.01% 2483
2024
Q3 		$265K Buy
12,852
+12,166
+1,773% +$623K 0.01% 1360
2024
Q2 		$31K Sell
686
-1,040
-60% -$43.7K ﹤0.01% 3464
2024
Q1 		$67.7K Buy
1,726
+536
+45% +$13.2K ﹤0.01% 2077
2023
Q4 		$7.19K Buy
+1,190
New +$6.39K ﹤0.01% 4646
2023
Q3 		– Sell
-147
Closed -$1.15K – 5983
2023
Q2 		$1.15K Sell
147
-388
-73% -$3.49K ﹤0.01% 5452
2023
Q1 		$4K Sell
535
-1,350
-72% -$5.91K ﹤0.01% 5057
2022
Q4 		$6K Buy
1,885
+1,638
+663% +$6.3K ﹤0.01% 4697
2022
Q3 		$1K Buy
+247
New +$1.74K ﹤0.01% 5744
2022
Q2 		– Sell
-303
Closed -$5K – 6122
2022
Q1 		$5K Buy
303
+217
+252% +$2.88K ﹤0.01% 5034
2021
Q4 		$2K Buy
86
+83
+2,767% +$2.25K ﹤0.01% 5608
2021
Q3 		$0 Sell
3
-563
-99% -$22.2K ﹤0.01% 5809
2021
Q2 		$31K Sell
566
-1,770
-76% -$98.2K ﹤0.01% 3446
2021
Q1 		$138K Buy
2,336
+1,316
+129% +$86.5K ﹤0.01% 2322
2020
Q4 		$38K Sell
1,020
-2,941
-74% -$110K ﹤0.01% 3368
2020
Q3 		$214K Buy
3,961
+3,148
+387% +$570K ﹤0.01% 2516
2020
Q2 		$205K Buy
+813
New +$164K 0.01% 1762
2020
Q1 		– Sell
-13
Closed -$2K – 3157
2019
Q4 		$2K Sell
13
-121
-90% -$17.9K ﹤0.01% 3028
2019
Q3 		$20K Buy
134
+131
+4,367% +$22.8K ﹤0.01% 2469
2019
Q2 		$1K Buy
+3
New +$642 ﹤0.01% 3412
2018
Q3 		– Sell
-162
Closed -$25K – 3823
2018
Q2 		$25K Buy
+162
New +$29.4K ﹤0.01% 2293
2018
Q1 		– Sell
-39
Closed -$8K – 3337
2017
Q4 		$8K Sell
39
-33
-46% -$7.06K ﹤0.01% 2660
2017
Q3 		$16K Buy
72
+45
+167% +$8.8K ﹤0.01% 2848
2017
Q2 		$5K Buy
+27
New +$5.29K ﹤0.01% 1970
2017
Q1 		– Sell
-17
Closed -$4K – 3166
2016
Q4 		$4K Buy
+17
New +$3.9K ﹤0.01% 3130
2016
Q2 		– Sell
-16
Closed -$1K – 4489
2016
Q1 		$1K Sell
16
-239
-94% -$10.5K ﹤0.01% 3656
2015
Q4 		$12K Buy
255
+250
+5,000% +$12.7K ﹤0.01% 1876
2015
Q3 		$0 Sell
5
-26
-84% -$1.73K ﹤0.01% 4099
2015
Q2 		$3K Buy
+31
New +$3.12K ﹤0.01% 3527

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Tower Research Capital (TRC)'s CRBP Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Corbus Pharmaceuticals (CRBP) in Q1 2026: 684 shares worth $6.42K. The stake represents ﹤0.01% of the portfolio and ranks #4057 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CRBP as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in CRBP in Q2 2015 and has held it in 32 quarters since. The position peaked at $265K in Q3 2024. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Tower Research Capital (TRC) held 684 shares of Corbus Pharmaceuticals worth $6.42K as of Q1 2026.
  • Corbus Pharmaceuticals was a new Tower Research Capital (TRC) position in Q1 2026.
  • Corbus Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4057 holding.
  • Tower Research Capital (TRC) first reported a position in Corbus Pharmaceuticals in Q2 2015 and has held it in 32 quarters since.
  • Tower Research Capital (TRC)'s Corbus Pharmaceuticals position peaked at $265K in Q3 2024.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.